Table 3:

Hazard ratios (HR) for new active brain lesions, relapses and time to sustained EDSS progression according to BMI categories--baseline to 60 months

	<18.5	18.5–<25	25–<30	≥30
	HR(95% CI)	Ref	HR(95% CI)	HR(95% CI)	P trend
New active brain lesions
All	1.11 (0.55–2.22)	1	1.18 (0.86–1.61)	1.34 (0.88–2.04)	0.14
Non-smokers	0.47 (0.18–1.23)	1	0.95 (0.62–1.45)	1.28 (0.75–2.18)	0.28
Active smokers	3.13 (1.04–9.39)	1	1.32 (0.79–2.21)	1.40 (0.70–2.79)	0.83
Relapses
All	0.71 (0.42–1.23)	1	1.12 (0.80–1.57)	1.53 (1.01–2.30)	0.03
Non-smokers	0.60 (0.28–1.28)	1	0.88 (0.56–1.38)	1.43 (0.87–2.34)	0.20
Active smokers	1.02 (0.37–2.90)	1	1.64 (0.93–2.90)	2.04 (0.99–4.19)	0.03
EDSS
All	1.16 (0.41–3.34)	1	1.09 (0.70–1.71)	0.89 (0.48–1.65)	0.82
Non-smokers	2.20 (0.56–8.6)	1	0.72 (0.36–1.42)	0.88 (0.39–1.99)	0.37
Active smokers	0.84 (0.10–6.81)	1	1.30 (0.61–2.77)	0.51 (0.15–1.71)	0.55

^*Adjusted model by age, sex, smoking status, region of residence, baseline serum levels of anti-EBV IgG antibodies, treatment allocation, treatment allocation, baseline serum 25(OH) vitamin D with seasonal correction, no. T2 lesions and brain volume at baseline, EDSS score, steroid treatment at baseline, and CIS onset type.